# SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

> **NCT00335166** · PHASE3 · COMPLETED · sponsor: **Solvay Pharmaceuticals** · enrollment: 330 (estimated)

## Conditions studied

- Early Stage Parkinson Disease

## Interventions

- **DRUG:** Pardaprunox
- **DRUG:** pramipexole
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT00335166
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2008-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335166, "SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00335166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*